Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial

Tang, Wei; Cao, Zhujun; Han, Mingfeng; Wang, Zhengyan; Chen, Junwen; Sun, Wenjin; Wu, Yaojie; Xiao, Wei; Liu, Shengyong; Chen, Erzhen; Chen, Wei; Wang, Xiongbiao; Yang, Jiuyong; Lin, Jun; Zhao, Qingxia; Yan, Youqin; Xie, Zhibin; Li, Dan; Yang, Yaofeng; Liu, Leshan; Qu, Jieming; Ning, Guang; Shi, Guochao; Xie, Qing

doi:10.1101/2020.04.10.20060558

Public

Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial

Published in medRxiv • Apr 14, 2020

Authors:

Wei Tang

Zhujun Cao

Mingfeng Han

Abstract

Abstract Objectives To assess the efficacy and safety of hydroxychloroquine (HCQ) plus standard–of–care (SOC) compared with SOC alone in adult patients with COVID–19. Design Multicenter, open–label, randomized controlled trial. Setting 16 government–designated COVID–19 treatment centers in China thr...

Subject

Medicine

Hydroxychloroquine

Confidence interval

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!